Christopher M. Hix
Net Worth
Last updated:
What is Christopher M. Hix net worth?
The estimated net worth of Mr. Christopher M. Hix is at least $37,635,926 as of 6 Sep 2025. He owns shares worth $21,321,206 as insider, has earned $3,174,720 from insider trading and has received compensation worth at least $13,140,000 in companies like Enovis Corporation, Colfax Corporation, Colfax Corporation etc.
What is the salary of Christopher M. Hix?
Mr. Christopher M. Hix salary is $1,150,000 per year as Executive Vice President of Fin. & Chief Financial Officer in Enovis Corporation. He also receives $1,090,000 as Executive Vice President of Fin. & Chief Financial Officer in Colfax Corporation and salaries from other companies.
How old is Christopher M. Hix?
Mr. Christopher M. Hix is 63 years old, born in 1962.
What stocks does Christopher M. Hix currently own?
As insider, Mr. Christopher M. Hix owns shares in 2 companies:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Colfax Corporation (CFX) | Executive Vice President of Fin. & Chief Financial Officer | 143,417 | $39.06 | $5,601,868 |
Colfax Corporation (CFXA) | Executive Vice President of Fin. & Chief Financial Officer | 88,455 | $177.71 | $15,719,338 |
What does Colfax Corporation do?
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.
What does Colfax Corporation do?
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.
Christopher M. Hix insider trading
Colfax Corporation
Mr. Christopher M. Hix has made 14 insider trades between 2019-2022, according to the Form 4 filled with the SEC. Most recently he sold 1,410 units of CFX stock worth $55,723 on 1 Mar 2022.
The largest trade he's ever made was exercising 19,330 units of CFX stock on 28 Feb 2022. As of 6 Sep 2025 he still owns at least 143,417 units of CFX stock.
Colfax Corporation
Mr. Christopher M. Hix has made 6 insider trades between 2020-2021, according to the Form 4 filled with the SEC. Most recently he sold 4,345 units of CFXA stock worth $192,614 on 14 Dec 2021.
The largest trade he's ever made was exercising 90,000 units of CFXA stock on 14 Jun 2021. As of 6 Sep 2025 he still owns at least 88,455 units of CFXA stock.
Enovis key executives
Enovis Corporation executives and other stock owners filed with the SEC:
- Mr. Bradley J. Tandy Senior Vice President, Gen. Counsel & Sec.
- Mr. Brady R. Shirley (59) Chief Executive Officer of DJO & Executive Vice President
- Mr. Christopher M. Hix (63) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Daniel A. Pryor (57) Executive Vice President of Strategy & Bus. Devel.
- Mr. Matthew L. Trerotola (58) Pres, Chief Executive Officer & Director
- Mr. Mitchell P. Rales (68) Co-Founder & Chairman
- Mr. Shyam Kambeyanda (54) Executive Vice President and Chief Executive Officer & Pres of ESAB
- Mr. Steven L. Breitzka Interim Senior Vice President of Global Operations & Americas
- Mr. Terry Ross Vice President of Investor Relations, Strategy & Bus. Devel.
- Ms. Patricia A. Lang Senior Vice President & Chief HR Officer